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Background: There have been several studies assessing the epidemiology and effects of tobacco smoke in the cystic ﬁbrosis (CF) population, but
few address the efforts of smoking cessation interventions. Our objective is to present one tobacco prevention and cessation programme targeting
patients with CF in the Mediterranean region of Murcia (Spain).
Methods: All registered patients in the Regional CF unit (n=105) in 2008 were included in a cross-sectional and prospective uncontrolled study of
tobacco use and exposure in CF patients using a baseline and 1-year follow-up. Target population includes both patients and other family members
living at home. The study included an initial telephone questionnaire, measurement of lung function, urinary cotinine levels, and several telephone
counselling calls and/or personalised smoking cessation services.
Results: Of the 97 contacted patients, 59.8% (n=58) were exposed to environmental tobacco smoke (ETS), 12.4% (n=12) had smoked at one time,
and 14.3% (n=8) of patients over the age of 15 actively smoked. The mean age was 31.13 (range: 19–45). Of the non-smokers (n=89), 56.2%
reported ETS and 26.9% live with at least one smoker at home. 49.2% had urinary cotinine levels N10 ng/ml. The correlation found between pa-
tients' cotinine levels and their reported tobacco exposure was (0.77, pb0.0001). Active smoking by mothers during pregnancy was associated
with signiﬁcantly lower lung function in young CF patients (−0.385, p=0.04). At the 1-year follow-up, 13 individuals made attempts to stop
smoking, 6 of which are now ex-smokers (12.5% of all smokers).
Conclusions: Smoking during pregnancy adversely affects lung function in individuals with CF. Tobacco prevention and cessation programmes
are an effective and vital component for CF disease management. The trained professionals in prevention and smoking cessation services could
provide patients with adequate follow-up, integrating an environmental health approach into CF patients' healthcare.
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among Caucasians. A life-shortening autosomal recessive disease
that affects the body's exocrine glands, its most prominent man-
ifestations include compromised function of the lungs, intestines,
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bidity and mortality in patients with CF [2]. Consequently, the
negative health effects of tobacco exposure in young patients
with CF are even greater than in healthy children [3].
There have been several papers assessing the incidence,
prevalence and negative effects of active and passive smoking
in the CF population. However, there are few reports on smok-
ing cessation interventions [4]. The objective of this paper is to
present the tobacco prevention and cessation programme target-
ing patients with CF in the Mediterranean region of Murcia,
Spain. We report the findings of a tobacco exposure question-
naire given to these patients, their correlations with urinary co-
tinine levels, the lung function and the result of the smoking
cessation interventions 1 year after start.
2. Methods
We conducted a cross-sectional and prospective uncontrolled
study of tobacco use and exposure in CF patients using a baseline
and 1-year follow-up in the Mediterranean region of Murcia,
Spain. The study included all registered patients in the Regional
CF Unit of the University Hospital Virgen of the Arrixaca from
1998 to 2008. As a result of the centralised attention of patients
with CF in Murcia, almost all patients diagnosed with CF in the
region (N95%) are included in this registry. Of the 120 registered
patients, 15 patients who had died were excluded. Only 6 patients
were diagnosed through neonatal screening, which was started in
Murcia in 2007; the rest were diagnosed by symptomatology. A
letter from the CF unit was initially mailed to all 105 patients
informing them of the programme's inception. The letter rein-
forced the importance of living tobacco-free in families of pa-
tients with CF and communicated that a trained professional
would be in contact in the coming weeks.
Families were contacted by telephone to schedule interviews.
Up to 9 attempts were made to establish telephone contact with
the patients. The interviews were conducted between June and
July 2008, and they lasted between 20 and 30 minutes. The ad-
ministered questionnaire specifically asked about the patient's
and family's tobacco use and exposure during different critical
periods in the patient's life. Family members included anyone
who lives with the patient (parents, siblings, spouse, or children
of the patient). We have used the following classification of
smoking [5]: 1. Non-smoker: a) not exposed to tobacco smoke,
and b) passive smoker, exposure to smoke from his/her friends
and/or parents and/or work and/or bars and/or others. 2. Occa-
sional smoker: does not smoke daily. 3. Smoker: smokes at
least 1 or more cigarettes/day. 4. Ex-smoker: does not smoke at
the time of the study, and has not smoked for at least 6 months.
The questionnaire also inquired about the number of ciga-
rettes smoked per week, age of smoking initiation and the
pack/years smoked by all of the patients, parents and relatives.
Moreover, we registered the patients' passive tobacco exposure
during the pre-gestational period (the year before the mother's
pregnancy and periconceptional period), the pregnancy, and
the postnatal period (up until the diagnosis). The questionnaire
also specifically asked about the many different sources of pos-
sible tobacco exposure in 2008: at home, work, in the car,places of leisure (no visits, 1 visit/week, 2–3 visits/week, N3
visits/week), restaurants/bars (no visits, 1 visit/week, 2–3
visits/week, N3 visits/week), and family visits (no visits, 1
visit/week, 2–3 visits/week, N3 visits/week). With all of these
data, we created a variable called “Global passive exposure,”
which collects any type of passive exposure of special interest,
especially in non-smoking patients. Other collected variables
included the family's monthly net income and the education
level of the patients and their parents.
A nurse from the Paediatric Environmental Health Specialty
Unit (Pehsu) with training and knowledge in smoking cessation
and prevention, telephone counselling and risk communication
carried out the smoking cessation counselling via telephone to
all smokers and non-smokers. This nurse took an interactive
training course with an appropriate balance between theoretical
(40 hours) and practical learning (100 hours).
The intervention included proactive telephone counselling that
used active recruitment and targeted both patients and other fam-
ilymembers living at home. The intervention had 4 principal mes-
sages: a) the short- and long-term effects of smoking in CF, with
an emphasis on the health benefits of quitting; b) strategies for
eliminating the patient's tobacco use and/or exposure; c) appropri-
ate motivation based on which stage in the process of abandoning
addictions the individual is at according to Prochaska and DiCle-
mente (i.e. pre-contemplation, contemplation, preparation, action,
and relapse); and, d) an offer of face-to-face tobacco cessation ser-
vices and telephone support tobacco cessation resources. During
the 1-year follow-up, sequenced calls from this trained cessation
counsellor were made every 6 months (no smoker at home) and
every 4 months (any smoker at home). When smokers agreeing
to make a quit attempt within 2 weeks are include in the cessation
sessions. Up to seven telephone assistance or face-to-face sessions
were available along 12 weeks. The process of effective tobacco-
use cessation counseling can be broken into 5 steps, called the 5
A's: ask, advise, assess, assist, and arrange follow-up. The inter-
vention included motivational interviewing, individual beha-
vioural counselling and nicotine replacement therapies [6]. The
smokers could “recycle” at least once if they failed to quit or to
maintain cessation.
In the same way, the CF and Paediatric Pulmonology units also
reinforce tobacco cessation during medical visits with brief mes-
sages and written leaflets. At the beginning of the program, the
forced expiratory volume in one second (FEV1), the forced vital
capacity (FVC) and FEV1/FVC were measured (all expressed as
a percentage of the predicted value). Data obtained before
5 years of age or after lung transplantationwere excluded. Cotinine
urine levels were also solicited from patients with CF who came to
the hospital for other purposes. Cotinine levels should be
below 10 ng/ml in patients not exposed to tobacco smoke, and
above that level, concentrations increase with increasing grade of
exposure. Cotinine has been studied as a valuable variable in inter-
vals (b10 ng/ml; 10–50 ng/ml; 51–200 ng/ml; 201–400 ng/ml;
N400 ng/ml). The patient's pseudomonas colonisation (yes/no)
was considered. To assess the effect of variation in the gene that
causes CF, participants were divided into three groups: those
with two copies of the most common mutation (F508del homozy-
gotes), those with one and those with no copies of that mutation.
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tables of the frequencies required for this study. In that way,
correlation studies with Spearman's rho were done on exposure
variables in the questionnaire and the urine cotinine levels of
the patients and other family members in the home.
For patients with CF aged 5–18 years, a stepwise linear re-
gression analysis was performed in which the outcome variables
were FEV1, CVF and FEV1/CVF. To obtain predictor variables
the comparisons of all variables were made using the unpaired
Student's t test, ANOVA test and Spearman's rho correlation.3. Results
Of the 105 available patients, 97 (92.3%) were successfully
contacted and followed. The participants demonstrated great in-
terest in participating, and they received telephone recommenda-
tions for smoking prevention and cessation. Nine individuals
(patients and parents) were seen in the clinic and utilised beha-
vioural therapy; in one of them, nicotine substitution therapy
was also used.Table 1
Socio-demographic variables.
Patients
CF patients per family
Only one 7
Two siblings 3
Three siblings 74
Sex
Male 55 (56.7
Female 42 (43.3
Age (mean) 18.66 (1
Number of smoked cigarettes/week (mean) 45.25 (1
Pack/years (mean) 6.71 (1.
Smoker (2008)
Yes 8 (8.2%
No 89 (91.8
Smokers in the home
None 65 (67.0%)
Only patient smokes 5 (5.2%)
Patient and others smoke 3 (3.1%)
Only others smoke 24 (24.7%)
Cotinine Level (ng/ml)
b10 35 (50.7
10–50 25 (36.2
51–200 2 (2.9%
201–400 2 (2.9%
N400 5 (7.2%
Level of education
None 32 (36.0
Primary 34 (38.2
Secondary 10 (11.2
University Studies Initiated 13 (14.6
Family's monthly net income (€)
b800 € 11 (15.1%)
800–1500 € 24 (32.9%)
1500–2000 € 16 (21.9%)
2000–2500 € 10 (13.7%)
2500–3500€ 11 (15.1%)
N3500 € 1 (1.4%)
Only 19 mothers and 17 fathers are smokers living with patients at home.Table 1 shows the general characteristics of the contacted
families at the moment of inclusion in the study and their actual
tobacco consumption in 2008. Table 2 describes exposure to to-
bacco smoke during critical periods in the patient's life, ranging
from the formation of the patient's germ cells (during the
grandmothers' pregnancies) to the moment of the first tele-
phone interview.3.1. Active smoking reported in the questionnaire
Out of the 97 contacted patients, 58 patients (59.8%) were
exposed to environmental tobacco smoke (ETS); 12.4%
(n=12) had smoked at one time and 8.2% (n=8) were currently
smoking; when considering patients over the age of 15, active
smokers represented 14.3%. The mean age was 31.13 (with a
range of 19 to 45). These patients smoked a mean 45.2 (95%
CI 13.07–77.43) cigarettes per week. They started smoking at
a mean age of 15.3 (95% CI 13.59–17.16), and had been smok-
ing for 15.75 years (95% CI 7.42–24.08). The mean pack-years
of smoking was 6.71 (95% CI 1.30–12.12). Of the patients thatMothers Fathers
%)
%)
6.22–21.10) 46.87 (44.27–49.47) 48.53 (45.94–51.12)
3.07–77.43) 89.66 (54.87–124.46) 138.15 (98.53–177.77)
30–12.12) 10.28 (5.47–15.09) 29.88 (20.82–38.93)
) 21 (21.6%) 24 (26.1%)
%) 76 (78.4%) 68 (73.9%)
%) 20 (38.5%) 10 (23.3%)
%) 16 (30.8%) 16 (37.2%)
) 4 (7.7%) 7 (16.3%)
) 1 (1.9%) 1 (2.3%)
) 11 (21.2%) 9 (20.9%)
%) 16 (19.0%) 16 (19.3%)
%) 39 (46.5%) 33 (39.7%)
%) 19 (22.6%) 16 (19.3%)
%) 10 (11.9%) 18 (21.7%)
Table 2
Environmental tobacco smoke exposure during different critical periods in the patient's life.
Periconceptional period Pregnancy Postnatal period Post-diagnosis At the present time (2008)
Smoking mothers 21 (21.9) 15 (15.6) 23 (24.0) 21 (21.9) 21 (21.6)
71.0 cig/week 38.3 cig/week 89.6 cig/week
Smoking fathers 43 (45.7) 43 (45.7) 44 (46.8) 34 (35.4) 24 (26.1)
149.8 cig/week 147.8 cig/week 138.1 cig/week
At home: 38.6 cig/week
Tobacco smoke exposure patients During oogenesis 56 (58.3) 73 (76.0) a 53 (55.8) b 45 (47.4) c Active smoker
8/97=8.2%
8/56 (N15 years)=14.3%
During spermatogenesis 24 (24.7)***
51 (53.1) 45.25 cig/week
a Refers to intrauterine tobacco exposure (a smoker at home, work, etc.).
b At least one smoker in the home after birth.
c At least one smoker in the home (not including the patient).
Table 4
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tive (pb0.001).
3.2. Passive smoking reported in the questionnaire
Of the 89 non-smoking patients, 56.2% (n=50) reported
some type of ETS at home, school, work and/or places like
bars and restaurants. 26.9% (n=24) of them live with at least
one smoker in the home. In those less than 15 years of age,
30.6% (n=11) accompany their parents to eat at a restaurant
with tobacco smoke at least once a week. Table 3 shows the
ETS exposure in and outside the home of non-smoking patients
with CF.
3.3. Correlations with urinary cotinine levels
Cotinine levels were analysed in 69 patients. 49.2% of pa-
tients had a cotinine level greater than 10 ng/ml. The Spearman
correlation is 0.77 (pb0.0001) between cotinine levels and the
tobacco smoke exposure of the patients reported in the ques-
tionnaire (3 categories: none, passive exposure, and smoker).
Also, excluding patient smokers, the study showed that there
was a difference in urinary tests for passive tobacco exposureTable 3
Environmental tobacco smoke exposure in non-smoking patients with CF
(2008).
Sources of tobacco smoke No smokers in
the home (n=65)
At least one smoker
in the home (n=24)
Restaurants 19 (29.2) 6 (25.0)
≤1 time/week 0 (0.0) 0 (0.0)
2–3 times/week 13 (68.4) 4 (66.7)
N3 times/week 6 (31.6) 2 (33.3)
Pubs, Bars, Clubs 8 (12.3) 3 (12.5)
≤1 time/week 7 (87.5) 2 (66.7)
2–3 times/week 1 (12.5) 1 (33.3)
N3 times/week 0 (0.0) 0 (0.0)
Other places with smoke
(houses of friends, family, etc.)
14 (21.5) 7 (29.1)
≤1 time/week 12 (85.7) 5 (71.4)
2–3 times/week 2 (14.3) 1 (14.3)
N3 times/week 0 (0.0) 1 (14.3)if any parents or relatives smoked inside as opposed to outside
the house (0.63, p=0.003). We found a negative correlation
with family's monthly net income (0.41, pb0.001) and no cor-
relation with any educational level.
Cotinine levels were analysed in 43 fathers and 52 mothers
and significant differences were found with their distributions
with smoking fathers and mothers, respectively (pb0.001).3.4. Smoking cessation
A total of 48 smokers were found (8 patients, 2 wives, 2 sib-
lings, 17 fathers, and 19 mothers). At the 12-month follow-up, se-
rious efforts were made to achieve smoking cessation in 13 people
(4 patients, 1 father, 8 mothers), ultimately leaving 6 (12.5%) of
them as non-smokers (2 patients, 1 father, and 3 mothers) during
the last 6 months (cooximetry of 0 in patients). Two patients
stopped smoking after going through a personalised consultation.
Additionally, a reduction in smoking behaviour was reported by
10 people (2 patients, 8 fathers).Stepwise linear regression of clinical end point with predictor variables in
patients aged 5–18 years.
Clinical
end point a
Predictor variable Regression
coefﬁcient
95% Conﬁdence
interval
p Value
FEV1 F508del homozygotes −0.511 −1.016 to
−0.048
0.034
Pseudomonas + −0.376 −0.741 to
−0.010
0.044
FVC F508 del homozygotes −0.551 −1.026 to
−0.072
0.027
F508 del heterozygotes −0.584 −0.943 to
–0.220
0.003
FEV1/FVC Smoking mother during
pregnancy (Cig/week)
−0.385 −0.416 to
−0.007
0.043
a Expressed as percentage predicted. The following predictor variables were
included: cotinine concentration, mother smoking during pregnancy (dicotou-
mus and cig/week), F508del groups, pseudomonas colonisation, smoking father
at home, father's packet per years. To obtain predictor variables the compari-
sons of all variables were made using the unpaired Student's t test, ANOVA
test and Spearman's rho correlation.
38 J.A. Ortega-García et al. / Journal of Cystic Fibrosis 11 (2012) 34–393.5. Lung function and gene–environment interactions
Table 4 shows the predictor variables that correlated signifi-
cantly with each clinical end point. The number of copies of
F508del was the most significant predictor of FEV1 and FVC.
Mothers who smoked during pregnancy (cig/week) were the
most significant predictor of FEV1/FVC.
4. Discussion
Spain has one of the highest rates of smoking in Europe
(29.5%), with an even higher rate in the Region of Murcia
(33.9%). The prevalence is 40.7% among Murcian men and
26.9% among women [7]. The 14.3% (n=8) of the patients
with CF in our study are active smokers, which is less than
the rest of the Spanish population and intermediate among the
8% [8], 11% [9], 16% [10], and 21% that other published CF
studies report. In general, it seems that CF was an important
reason to not start smoking— an encouraging finding since
the disease processes accompanying CF are likely to be exacer-
bated by tobacco use. Smoking is known to irritate mucosal lin-
ings and increase coughing and phlegm production in the
respiratory tract, resulting in increased likelihood of bacterial
infections, worsening of symptoms, and increased hospitalisa-
tions. Several studies have even found a dose-dependent rela-
tionship between the number of cigarettes smoked and the
severity of respiratory disease among young patients with CF
[3,8,11].
Despite the absence of adolescent smokers in our study,
about a third (36.5%) of CF patients under the age of 19 live
with at least one smoker in the home, compared to 50% of
healthy children in the Murcia Region [12]. Also, nearly 60%
of our patients are exposed to tobacco smoke in places that
should be more secure, such as at home or work (either because
they themselves are smokers or because they are exposed to it
by their relatives, colleagues, or others). These rates are alarm-
ing given that CF patients exposed to secondhand smoke in the
home has been associated with a 10% reduction in pulmonary
function [13]. Tobacco smoke demonstrates diminished nasal
and sinus mucociliary clearance [14], and it can also diminish
the benefits of respiratory therapy in these patients, further lim-
iting their cardio-respiratory capacity. Smoking may also result
in appetite reduction and weight loss, which can be problematic
in youngsters with CF who already have poor growth patterns
and gastrointestinal complications.
The effect of prenatal tobacco exposure on infant pulmonary
function is well known. We have shown a negative association
between smoking during pregnancy and lung function in young
patients with CF. We speculate that active maternal smoking
during pregnancy negatively affects critical periods of lung de-
velopment. For every additional 10 cigarettes smoked per
week, the FEV1/FVC decreased by about 3–4%. A difference
of our findings from previous studies is that the gene that
causes CF does not amplify the negative effects of secondhand
smoke exposure [13].
This study has several limitations, most notably the small
sample size and the difficulty of characterising environmentaltobacco exposure through a telephone interview. Recall bias
is a concern when information is collected retrospectively.
The ubiquity, widespread exposure, and temporal dimension
of tobacco smoke makes it difficult to interpret the concept of
passive tobacco exposure and explains the large differences
found in the literature, ranging from 23% [13] to 76% [8]. In
order to verify the tobacco use and exposure reported in the
questionnaire, we tried to reduce recall by conducting inter-
views by one trained professional. The calls were made by
one nurse trained in tobacco cessation and motivational inter-
views, and the cotinine levels of patients and other family mem-
bers were collected given that previous studies have found
elevated urinary cotinine levels in CF patients who smoked
compared to controls [3]. The correlation between grade of ex-
posure among the patients via the questionnaire and their uri-
nary cotinine levels was strong (0.77). We think that this is
due to the experience and training applied when collecting the
information. The cotinine levels are a valuable measure of ex-
posure that could be collected annually since it is rapid, non-in-
vasive and easy to interpret.
In order to further reduce recall bias, linear regression anal-
ysis with all these variables and other clinical endpoints of lung
function were limited to patients younger than 18 years old.
Finally, the effect of other confounding variables could also
be present such as nutritional status and others. This study is an
ongoing project and we hope conduct further analyses in the
future.
Telephone counselling (OR 1.56, CI: 1.38–1.77) and nurs-
ing interventions (OR 1.47, CI: 1.29–1.67) are effective ap-
proaches to smoking cessation [15], and nurses trained in
these methods have been shown to improve the results of inter-
ventions [16]. Pehsu can help to train and support nurses in this
task [17–19]. In light of this, one nurse specially trained in
smoking cessation and environmental health conducted the
telephone interviews carried out in this study. According to par-
ticipative response from participants, the frequency of phone
calls seems to be adequate in our population.
The lack of a control group in this study prevents an estimation
of the real impact of this approach. However, due to ethical con-
siderations, we do not believe it would have been appropriate to
deny available treatment to patients exposed to tobacco smoke.
Despite this fact, our minimal-cost interventions resulted in seri-
ous attempts to quit smoking by 13 people, 6 of which were ulti-
mately successful, and smoking reductions in 10 others. While
we present encouraging follow-up results for the first year of
the programme, it is necessary to consider that smoking cessation
interventions need to be maintained and prolonged in time. Re-
lapses can be frequent, and relatives who smoke need continual
smoking cessation advice and support from the paediatric multi-
disciplinary team in order to stop smoking and eliminate the dam-
aging effects of tobacco on their child. CF units should also
actively discourage smoking initiation in their younger patients,
and if they do start smoking, a comprehensive cessation pro-
gramme should be in place. Our interventional model comple-
ments the activities of CF units with the actions and support of
a Pehsu. The European Environment and Health Action Plan
(CEHAPE) recognises that Pehsu should be created [20]. These
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sure to tobacco—a life-threatening environmental toxin in this
vulnerable population. They could help patients by integrating in-
formation and human resources that are trained and can provide
adequate follow-up, smoking cessation services, help in finding
the most appropriate cessation intervention, and a wide range
of specific and personalised information on smoking and health-
related needs in order to prevent smoking before it starts and
help patients and relatives remain abstinent.
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